Why the study?
Does an intensified schedule of epirubicin improve response rate and time to progression in patients with previously untreated advanced breast cancer?
Population
141 fully assessable patients with previously untreated advanced breast cancer
Comparison
Intensified schedule of epirubicin 50 mg/m2 on… vs Non-intensified program of epirubicin 50 mg/m2…
Design
RCT, randomized
Authors
Loading...
Supports intensified epirubicin scheduling in advanced breast cancer; extends evidence for dose intensity in metastatic disease.
Does an intensified schedule of epirubicin improve response rate and time to progression in patients with previously untreated advanced breast cancer?
An intensified schedule of epirubicin significantly improves response rate, response duration, and time to progression in advanced breast cancer compared to a standard schedule.
Focan et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: